Preclinical characterization of Aurora kinase inhibitor R763/AS703569 identified through an image-based phenotypic screen

Journal of Cancer Research and Clinical Oncology

Volumn 136, Issue 1, 2010, Pages 99-113

  McLaughlin, John ^a   Markovtsov, Vadim ^a   Li, Hui ^a   Wong, Steve ^a   Gelman, Marina ^a   Zhu, Yanhong ^a   Franci, Christian ^a   Lang, D Wayne ^a   Pali, Erlina ^a   Lasaga, Joe ^a   Low, Caroline ^a   Zhao, Feifei ^a   Chang, Betty ^a   Gururaja, Tarikere L ^a   Xu, Weiduan ^a   Baluom, Muhammad ^a   Sweeny, David ^a   Carroll, David ^a   Sran, Arvinder ^a   Thota, Sambaiah ^a   Parmer, Manjeet ^a   Romane, Angela ^b   Clemens, George ^a   Grossbard, Elliott ^a   Qu, Kunbin ^a   Jenkins, Yonchu ^a   Kinoshita, Taisei ^a   Taylor, Vanessa ^a   Holland, Sacha J ^a   Argade, Ankush ^a   Singh, Rajinder ^a   Pine, Polly ^a   Payan, Donald G ^a   Hitoshi, Yasumichi ^a   more..

^a RIGEL PHARMACEUTICALS INC   (United States)

^b EMD SERONO INC   (United States)

Author keywords

Anti neoplastic agents; Aurora kinases; Cytokinesis; Mitosis; Neoplasm; Protein kinase inhibitors; Protein kinases

Indexed keywords

ADENOSINE KINASE; AS 703569; AURORA A KINASE; AURORA B KINASE; AURORA C KINASE; AURORA KINASE INHIBITOR; CD135 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE; INSULIN RECEPTOR KINASE; PROTEIN KINASE B; R 763; STRESS ACTIVATED PROTEIN KINASE; TRANSFORMING GROWTH FACTOR BETA ACTIVATED KINASE 1; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR 2;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BREAST TUMOR; CANCER CELL CULTURE; CANCER INHIBITION; CANCER RESISTANCE; CELL ENLARGEMENT; CELL SCREENING; CELL SIZE; CELL TYPE; COLON TUMOR; CONTROLLED STUDY; DRUG EFFICACY; DRUG SCREENING; DRUG SENSITIVITY; DRUG WITHDRAWAL; ENDOREDUPLICATION; FEMALE; HUMAN; HUMAN CELL; IMAGE ANALYSIS; IN VITRO STUDY; IN VIVO STUDY; LEUKEMIA CELL LINE; LUNG TUMOR; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; OVARY CARCINOMA; OVARY TUMOR; PANCREAS TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; TANDEM REPEAT; XENOGRAFT;

ANIMALS; APOPTOSIS; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; FEMALE; FLOW CYTOMETRY; HELA CELLS; HL-60 CELLS; HUMANS; MICE; MICE, INBRED NOD; MICE, INBRED STRAINS; MICE, NUDE; MICE, SCID; MICROSCOPY, FLUORESCENCE; PROTEIN KINASE INHIBITORS; PROTEIN-SERINE-THREONINE KINASES; SURVIVAL ANALYSIS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 71449112904     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-009-0641-1     Document Type: Article

References (72)

1. RR Adams SP Wheatley AM Gouldsworthy SE Kandels-Lewis M Carmena C Smythe, et al. 2000 INCENP binds the Aurora-related kinase AIRK2 and is required to target it to chromosomes, the central spindle and cleavage furrow Curr Biol 10 17 1075 1078 10.1016/S0960-9822(00)00673-4 10996078
2. K Araki K Nozaki T Ueba M Tatsuka N Hashimoto 2004 High expression of Aurora-B/Aurora and Ipll-like midbody-associated protein (AIM-1) in astrocytomas J Neurooncol 67 1-2 53 64 10.1023/B:NEON.0000021784.33421.05 15072448 (Pubitemid 38418249)
3. A Barabasz B Foley JC Otto A Scott J Rice 2006 The use of high-content screening for the discovery and characterization of compounds that modulate mitotic index and cell cycle progression by differing mechanisms of action Assay Drug Dev Technol 4 2 153 163 10.1089/adt.2006.4.153 16712419 (Pubitemid 43810919)
4. R Bayliss T Sardon I Vernos E Conti 2003 Structural basis of Aurora-A activation by TPX2 at the mitotic spindle Mol Cell 12 4 851 862 10.1016/S1097-2765(03)00392-7 14580337 (Pubitemid 37352779)
5. JR Bischoff L Anderson Y Zhu K Mossie L Ng B Souza, et al. 1998 A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers EMBO J 17 11 3052 3065 10.1093/emboj/17.11.3052 9606188 (Pubitemid 28254378)
6. HM Buschhorn RR Klein SM Chambers MC Hardy S Green D Bearss, et al. 2005 Aurora-A over-expression in high-grade PIN lesions and prostate cancer Prostate 64 4 341 346 10.1002/pros.20247 15754349 (Pubitemid 41193246)
7. M Carmena WC Earnshaw 2003 The cellular geography of aurora kinases Nat Rev Mol Cell Biol 4 11 842 854 10.1038/nrm1245 14625535 (Pubitemid 37411723)
8. P Carpinelli R Ceruti ML Giorgini P Cappella L Gianellini V Croci, et al. 2007 PHA-739358, a potent inhibitor of Aurora kinases with a selective target inhibition profile relevant to cancer Mol Cancer Ther 6 12 Pt 1 3158 3168 10.1158/1535-7163.MCT-07-0444 18089710
9. F Chan C Sun M Perumal QD Nguyen V Bavetsias E McDonald, et al. 2007 Mechanism of action of the Aurora kinase inhibitor CCT129202 and in vivo quantification of biological activity Mol Cancer Ther 6 12 Pt 1 3147 3157 10.1158/1535-7163.MCT-07-2156 18089709
10. P Chieffi G Troncone A Caleo S Libertini S Linardopoulos D Tramontano, et al. 2004 Aurora B expression in normal testis and seminomas J Endocrinol 181 2 263 270 10.1677/joe.0.1810263 15128274 (Pubitemid 38744675)
11. P Chieffi L Cozzolino A Kisslinger S Libertini S Staibano G Mansueto, et al. 2006 Aurora B expression directly correlates with prostate cancer malignancy and influence prostate cell proliferation Prostate 66 3 326 333 10.1002/pros.20345 16267859 (Pubitemid 43191232)
12. TF Chu MA Rupnick R Kerkela SM Dallabrida D Zurakowski L Nguyen, et al. 2007 Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib Lancet 370 9604 2011 2019 10.1016/S0140-6736(07)61865-0 18083403 (Pubitemid 350236338)
13. AG Cochran 2008 Aurora A: target invalidated? Chem Biol 15 6 525 526 10.1016/j.chembiol.2008.06.002 18559262 (Pubitemid 351815062)
14. C Ditchfield VL Johnson A Tighe R Ellston C Haworth T Johnson, et al. 2003 Aurora B couples chromosome alignment with anaphase by targeting BubR1, Mad2, and Cenp-E to kinetochores J Cell Biol 161 2 267 280 10.1083/jcb.200208091 12719470 (Pubitemid 36529846)
15. S Emanuel CA Rugg RH Gruninger R Lin A Fuentes-Pesquera PJ Connolly, et al. 2005 The in vitro and in vivo effects of JNJ-7706621: a dual inhibitor of cyclin-dependent kinases and aurora kinases Cancer Res 65 19 9038 9046 10.1158/0008-5472.CAN-05-0882 16204078 (Pubitemid 41377396)
16. Escudier B, Koralewski P, Pluzanska A, Ravaud A, Bracarda S, Szczylik C et al (2007) A randomized, controlled, double-blind phase III study (AVOREN) of bevacizumab/interferon-α2a vs placebo/interferon-α2a as first-line therapy in metastatic renal cell carcinoma. In: Annual meeting of the American society of clinical oncology 2007, Chicago, IL, 1-5 June 2007
17. D Fancelli D Berta S Bindi A Cameron P Cappella P Carpinelli, et al. 2005 Potent and selective Aurora inhibitors identified by the expansion of a novel scaffold for protein kinase inhibition J Med Chem 48 8 3080 3084 10.1021/jm049076m 15828847 (Pubitemid 40548120)
18. F Girdler F Sessa S Patercoli F Villa A Musacchio S Taylor 2008 Molecular basis of drug resistance in aurora kinases Chem Biol 15 6 552 562 10.1016/j.chembiol.2008.04.013 18559266 (Pubitemid 351815053)
19. F Gizatullin Y Yao V Kung MW Harding M Loda GI Shapiro 2006 The Aurora kinase inhibitor VX-680 induces endoreduplication and apoptosis preferentially in cells with compromised p53-dependent postmitotic checkpoint function Cancer Res 66 15 7668 7677 10.1158/0008-5472.CAN-05-3353 16885368 (Pubitemid 44289225)
20. TM Gritsko D Coppola JE Paciga L Yang M Sun SA Shelley, et al. 2003 Activation and overexpression of centrosome kinase BTAK/Aurora-A in human ovarian cancer Clin Cancer Res 9 4 1420 1426 12684414
21. AW Hamburger SE Salmon 1977 Primary bioassay of human tumor stem cells Science 197 4302 461 463 10.1126/science.560061 560061
22. EA Harrington D Bebbington J Moore RK Rasmussen AO Ajose-Adeogun T Nakayama, et al. 2004 VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo Nat Med 10 3 262 267 10.1038/nm1003 14981513 (Pubitemid 38667616)
23. Haskell C (2001) Cancer treatment, 5th edn. Elsevier, Philadelphia
24. T Hata T Furukawa M Sunamura S Egawa F Motoi N Ohmura, et al. 2005 RNA interference targeting aurora kinase A suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells Cancer Res 65 7 2899 2905 10.1158/0008-5472.CAN-04-3981 15805292 (Pubitemid 40490094)
25. S Hauf RW Cole S LaTerra C Zimmer G Schnapp R Walter, et al. 2003 The small molecule Hesperadin reveals a role for Aurora B in correcting kinetochore-microtubule attachment and in maintaining the spindle assembly checkpoint J Cell Biol 161 2 281 294 10.1083/jcb.200208092 12707311 (Pubitemid 36529847)
26. NM Heron M Anderson DP Blowers J Breed JM Eden S Green, et al. 2006 SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors Bioorg Med Chem Lett 16 5 1320 1323 10.1016/j.bmcl.2005.11.053 16337122 (Pubitemid 43143015)
27. T Hirota N Kunitoku T Sasayama T Marumoto D Zhang M Nitta, et al. 2003 Aurora-A and an interacting activator, the LIM protein Ajuba, are required for mitotic commitment in human cells Cell 114 5 585 598 10.1016/S0092-8674(03) 00642-1 13678582 (Pubitemid 37159255)
28. K Hoar A Chakravarty C Rabino D Wysong D Bowman N Roy, et al. 2007 MLN8054, a small-molecule inhibitor of Aurora A, causes spindle pole and chromosome congression defects leading to aneuploidy Mol Cell Biol 27 12 4513 4525 10.1128/MCB.02364-06 17438137 (Pubitemid 46906573)
29. A Hoque J Carter W Xia MC Hung AA Sahin S Sen, et al. 2003 Loss of aurora A/STK15/BTAK overexpression correlates with transition of in situ to invasive ductal carcinoma of the breast Cancer Epidemiol Biomarkers Prev 12 12 1518 1522 14693746
30. H Hurwitz L Fehrenbacher W Novotny T Cartwright J Hainsworth W Heim, et al. 2004 Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 23 2335 2342 10.1056/NEJMoa032691 15175435 (Pubitemid 38702844)
31. Hutcheson, Matthew C (1995) Trimmed resistant weighted scatterplot smooth. Thesis (MS), Department of Statistics, Cornell University, Ithaca, NY
32. YM Jeng SY Peng CY Lin HC Hsu 2004 Overexpression and amplification of Aurora-A in hepatocellular carcinoma Clin Cancer Res 10 6 2065 2071 10.1158/1078-0432.CCR-1057-03 15041727 (Pubitemid 38375568)
33. FH Jung G Pasquet C Lambert-van der Brempt JJ Lohmann N Warin F Renaud, et al. 2006 Discovery of novel and potent thiazoloquinazolines as selective Aurora A and B kinase inhibitors J Med Chem 49 3 955 970 10.1021/jm050786h 16451062
34. FF Kabbinavar J Hambleton RD Mass HI Hurwitz E Bergsland S Sarkar 2005 Combined analysis of efficacy: the addition of bevacizumab to fluorouracil/leucovorin improves survival for patients with metastatic colorectal cancer J Clin Oncol 23 16 3706 3712 10.1200/JCO.2005.00.232 15867200 (Pubitemid 46252465)
35. FF Kabbinavar J Schulz M McCleod T Patel JT Hamm JR Hecht, et al. 2005 Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial J Clin Oncol 23 16 3697 3705 10.1200/JCO.2005.05.112 15738537 (Pubitemid 46252464)
36. S Kaitna M Mendoza V Jantsch-Plunger M Glotzer 2000 Incenp and an aurora-like kinase form a complex essential for chromosome segregation and efficient completion of cytokinesis Curr Biol 10 19 1172 1181 10.1016/S0960-9822(00)00721-1 11050385 (Pubitemid 30816678)
37. TA Kufer HH Sillje R Korner OJ Gruss P Meraldi EA Nigg 2002 Human TPX2 is required for targeting Aurora-A kinase to the spindle J Cell Biol 158 4 617 623 10.1083/jcb.200204155 12177045 (Pubitemid 34920101)
38. M Kurai T Shiozawa HC Shih T Miyamoto YZ Feng H Kashima, et al. 2005 Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora B as a predictor for poor prognosis in endometrial carcinoma Hum Pathol 36 12 1281 1288 10.1016/j.humpath.2005.09.014 16311121 (Pubitemid 41682283)
39. EC Lee A Frolov R Li G Ayala NM Greenberg 2006 Targeting aurora kinases for the treatment of prostate cancer Cancer Res 66 10 4996 5002 10.1158/0008-5472.CAN-05-2796 16707419 (Pubitemid 43844918)
40. MG Manfredi JA Ecsedy KA Meetze SK Balani O Burenkova W Chen, et al. 2007 Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase Proc Natl Acad Sci USA 104 10 4106 4111 10.1073/pnas.0608798104 17360485 (Pubitemid 47181586)
41. T Marumoto S Honda T Hara M Nitta T Hirota E Kohmura, et al. 2003 Aurora-A kinase maintains the fidelity of early and late mitotic events in Hela cells J Biol Chem 278 51 51786 51795 10.1074/jbc.M306275200 14523000 (Pubitemid 38020425)
42. T Marumoto D Zhang H Saya 2005 Aurora-A-a guardian of poles Nat Rev Cancer 5 1 42 50 10.1038/nrc1526 15630414 (Pubitemid 40052324)
43. Y Miyoshi K Iwao C Egawa S Noguchi 2001 Association of centrosomal kinase STK15/BTAK mRNA expression with chromosomal instability in human breast cancers Int J Cancer 92 3 370 373 10.1002/ijc.1200 11291073 (Pubitemid 32249713)
44. G Moreno-Bueno C Sanchez-Estevez R Cassia S Rodriguez-Perales R Diaz-Uriarte O Dominguez, et al. 2003 Differential gene expression profile in endometrioid and nonendometrioid endometrial carcinoma: STK15 is frequently overexpressed and amplified in nonendometrioid carcinomas Cancer Res 63 18 5697 5702 14522886
45. RJ Motzer MD Michaelson BG Redman GR Hudes G Wilding RA Figlin, et al. 2006 Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma J Clin Oncol 24 1 16 24 10.1200/JCO.2005.02.2574 16330672 (Pubitemid 46630489)
46. K Neben A Korshunov A Benner G Wrobel M Hahn F Kokocinski, et al. 2004 Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival Cancer Res 64 9 3103 3111 10.1158/0008-5472.CAN-03-3968 15126347 (Pubitemid 38581410)
47. S Rojanala H Han RM Munoz W Browne R Nagle DD Von Hoff, et al. 2004 The mitotic serine threonine kinase, Aurora-2, is a potential target for drug development in human pancreatic cancer Mol Cancer Ther 3 4 451 457 15078988
48. ME Royce W Xia AA Sahin H Katayama DA Johnston G Hortobagyi, et al. 2004 STK15/Aurora-A expression in primary breast tumors is correlated with nuclear grade but not with prognosis Cancer 100 1 12 19 10.1002/cncr.11879 14692019 (Pubitemid 37553534)
49. C Sakakura A Hagiwara R Yasuoka Y Fujita M Nakanishi K Masuda, et al. 2001 Tumour-amplified kinase BTAK is amplified and overexpressed in gastric cancers with possible involvement in aneuploid formation Br J Cancer 84 6 824 831 10.1054/bjoc.2000.1684 11259099 (Pubitemid 32275658)
50. A Sandler R Gray MC Perry J Brahmer JH Schiller A Dowlati, et al. 2006 Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 24 2542 2550 10.1056/NEJMoa061884 17167137 (Pubitemid 44917502)
51. FA Scappaticci L Fehrenbacher T Cartwright JD Hainsworth W Heim J Berlin, et al. 2005 Surgical wound healing complications in metastatic colorectal cancer patients treated with bevacizumab J Surg Oncol 91 3 173 180 10.1002/jso.20301 16118771 (Pubitemid 41254420)
52. S Sen H Zhou RA White 1997 A putative serine/threonine kinase encoding gene BTAK on chromosome 20q13 is amplified and overexpressed in human breast cancer cell lines Oncogene 14 18 2195 2200 10.1038/sj.onc.1201065 9174055
53. S Sen H Zhou RD Zhang DS Yoon F Vakar-Lopez S Ito, et al. 2002 Amplification/overexpression of a mitotic kinase gene in human bladder cancer J Natl Cancer Inst 94 17 1320 1329 12208897
54. F Sessa M Mapelli C Ciferri C Tarricone LB Areces TR Schneider, et al. 2005 Mechanism of Aurora B activation by INCENP and inhibition by hesperadin Mol Cell 18 3 379 391 10.1016/j.molcel.2005.03.031 15866179 (Pubitemid 41350542)
55. SL Smith NL Bowers DC Betticher O Gautschi D Ratschiller PR Hoban, et al. 2005 Overexpression of aurora B kinase (AURKB) in primary non-small cell lung carcinoma is frequent, generally driven from one allele, and correlates with the level of genetic instability Br J Cancer 93 6 719 729 10.1038/sj.bjc.6602779 16222316 (Pubitemid 41486464)
56. C Soncini P Carpinelli L Gianellini D Fancelli P Vianello L Rusconi, et al. 2006 PHA-680632, a novel Aurora kinase inhibitor with potent antitumoral activity Clin Cancer Res 12 13 4080 4089 10.1158/1078-0432.CCR-05-1964 16818708 (Pubitemid 44078096)
57. R Sorrentino S Libertini PL Pallante G Troncone L Palombini V Bavetsias, et al. 2005 Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation J Clin Endocrinol Metab 90 2 928 935 10.1210/jc.2004-1518 15562011 (Pubitemid 40279218)
58. T Takahashi M Futamura N Yoshimi J Sano M Katada Y Takagi, et al. 2000 Centrosomal kinases, HsAIRK1 and HsAIRK3, are overexpressed in primary colorectal cancers Jpn J Cancer Res 91 10 1007 1014 11050471
59. T Tanaka M Kimura K Matsunaga D Fukada H Mori Y Okano 1999 Centrosomal kinase AIK1 is overexpressed in invasive ductal carcinoma of the breast Cancer Res 59 9 2041 2044 10232583
60. E Tanaka Y Hashimoto T Ito T Okumura T Kan G Watanabe, et al. 2005 The clinical significance of Aurora-A/STK15/BTAK expression in human esophageal squamous cell carcinoma Clin Cancer Res 11 5 1827 1834 10.1158/1078-0432.CCR-04- 1627 15756006 (Pubitemid 40471846)
61. MM Tanner S Grenman A Koul O Johannsson P Meltzer T Pejovic, et al. 2000 Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer Clin Cancer Res 6 5 1833 1839 10815905
62. M Tatsuka H Katayama T Ota T Tanaka S Odashima F Suzuki, et al. 1998 Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells Cancer Res 58 21 4811 4816 9809983
63. Y Terada M Tatsuka F Suzuki Y Yasuda S Fujita M Otsu 1998 AIM-1: a mammalian midbody-associated protein required for cytokinesis EMBO J 17 3 667 676 10.1093/emboj/17.3.667 9450992 (Pubitemid 28062046)
64. SL Warner S Bashyam H Vankayalapati DJ Bearss H Han D Mahadevan, et al. 2006 Identification of a lead small-molecule inhibitor of the Aurora kinases using a structure-assisted, fragment-based approach Mol Cancer Ther 5 7 1764 1773 10.1158/1535-7163.MCT-05-0524 16891462 (Pubitemid 44323244)
65. T Watanabe I Imoto T Katahira A Hirasawa I Ishiwata M Emi, et al. 2002 Differentially regulated genes as putative targets of amplifications at 20q in ovarian cancers Jpn J Cancer Res 93 10 1114 1122 12417041
66. SP Wheatley A Carvalho P Vagnarelli WC Earnshaw 2001 INCENP is required for proper targeting of Survivin to the centromeres and the anaphase spindle during mitosis Curr Biol 11 11 886 890 10.1016/S0960-9822(01)00238-X 11516652 (Pubitemid 32532816)
67. RW Wilkinson R Odedra SP Heaton SR Wedge NJ Keen C Crafter, et al. 2007 AZD1152, a selective inhibitor of Aurora B kinase, inhibits human tumor xenograft growth by inducing apoptosis Clin Cancer Res 13 12 3682 3688 10.1158/1078-0432.CCR-06-2979 17575233 (Pubitemid 46955132)
68. Y Yakushijin M Hamada M Yasukawa 2004 The expression of the aurora-A gene and its significance with tumorigenesis in non-Hodgkin's lymphoma Leuk Lymphoma 45 9 1741 1746 10.1080/10428190410001683615 15223631 (Pubitemid 38997139)
69. JC Yang L Haworth RM Sherry P Hwu DJ Schwartzentruber SL Topalian, et al. 2003 A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 5 427 434 10.1056/NEJMoa021491 12890841 (Pubitemid 36910021)
70. H Yang T Burke J Dempsey B Diaz E Collins J Toth, et al. 2005 Mitotic requirement for aurora A kinase is bypassed in the absence of aurora B kinase FEBS Lett 579 16 3385 3391 10.1016/j.febslet.2005.04.080 15922328 (Pubitemid 40800286)
71. J Zhou P Giannakakou 2005 Targeting microtubules for cancer chemotherapy Curr Med Chem Anticancer Agents 5 1 65 71 10.2174/1568011053352569 15720262 (Pubitemid 40081295)
72. H Zhou J Kuang L Zhong WL Kuo JW Gray A Sahin, et al. 1998 Tumour amplified kinase STK15/BTAK induces centrosome amplification, aneuploidy and transformation Nat Genet 20 2 189 193 10.1038/2496 9771714 (Pubitemid 28455454)